TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03797469

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B3
Description: 3 tablets of 1000 mg each will be administered orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvate
Description: 2 tablets of 1500 mg each will be administered orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
Study: NCT02886143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Voiding Trial
Description: Nursing protocol:~1. Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~2. Clamp the Foley~3. Deflate the catheter balloon and remove the catheter from the bladder.~4. Record the amount of saline that was instilled into the bladder.~5. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive Voiding Trial
Description: Nursing protocol:~1. Deflate the catheter balloon and remove the catheter from the bladder.~2. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~3. 5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter
Study: NCT06033079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
Study: NCT03430921

Intervention type: DEVICE
Group type: OTHER
Intervention: Enlighten™ Laser and a MLA Attachment
Description: Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
Study: NCT04892836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
Study: NCT02626507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
Study: NCT03355300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT03565627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise app: 7 Minute Workout Challenge
Description: 7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Running app: One You Couch to 5K
Description: One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
Study: NCT03042507

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
Study: NCT04372277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: topical Enstilar foam
Study: NCT01051427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiflo
Description: Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal catheter
Description: In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
Study: NCT03048422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: One 50 mg DTG tablet was administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: One 50 mg DTG tablet was administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir alafenamide
Description: One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
Study: NCT00800501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029
Description: Continuous ICV infusion at one of three dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous ICV infusion
Study: NCT02922140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pharmaceutical care service
Study: NCT03116932

Intervention type: BEHAVIORAL
Intervention: PrEP knowledge and acceptability questionnaire
Description: This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
Study: NCT00939900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (aclasta)
Description: Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
Study: NCT06162910

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daniels Water Swallow Test
Description: Clinical water swallow dysphagia screening

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flexible Endoscopic Evaluation of Swallowing
Description: Endoscopic evaluation of swallowing function
Study: NCT04391699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidification
Description: heated humidification system
Study: NCT00653003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: tablets, 20mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA
Description: Tablets, 20mg, single-dose
Study: NCT00811772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of one or more bare metal stent(s)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of one or more drug eluting stent(s)
Study: NCT04156451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg
Description: Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg
Description: active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
Study: NCT02883946

Intervention type: OTHER
Intervention: Data collection
Study: NCT02484911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5mg,twice a day orally on day 1 to day 4

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: 125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: 0.25mg IV 30-60min before chemotherapy on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25mg IV 30-60min before chemotherapy on day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: 6mg IV on day 1 ，3.75mg IV on day 2 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6mg IV on day 1 ，3.75mg IV on day 2 to 4
Study: NCT04185688

Intervention type: OTHER
Intervention: Functional Reach Test
Description: The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.

Intervention type: OTHER
Intervention: Functional Reach Test
Description: The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
Study: NCT01347151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The glidescope video laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pentax airwayscope
Study: NCT01225484

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block + periarticular infiltration
Description: Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block + periarticular infiltration
Description: Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular and periarticular ropivacaine
Description: Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
Study: NCT04194099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS (Brain)
Description: Higher frequency (\>5 Hz) trains increase cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS (Brain)
Description: Higher frequency (\>5 Hz) trains increase cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS rTMS (Brain)
Description: Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS rTMS (Brain)
Description: Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anode tsDCS (Spinal)
Description: Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anode tsDCS (Spinal)
Description: Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz current square-wave pulses (Spinal)
Description: Higher frequency (\>5 Hz) of current increase cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS (Spinal)
Description: Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: with sham stimulation on brain and spinal.
Study: NCT01116908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeStraw Family
Description: LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
Study: NCT04315519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic Exercise
Study: NCT04071184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alofanib
Description: Five dose cohorts and expanded cohort will be included
Study: NCT04559958

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue image
Description: capture tongue images by Automatic Tongue Diagnosis System
Study: NCT03451773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 or 500mg every 2 weeks by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 or 500mg every 2 weeks by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
Study: NCT01409135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-22M6E
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-22CE
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-22CE
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-22CE
Description: IV Infusion
Study: NCT01028664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: 2-hour continuous IOP monitoring
Study: NCT04766307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Study: NCT00980200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4 QD
Description: QD once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3 QD
Description: QD once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 QD
Description: QD once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 BD
Description: BD twice daily
Study: NCT02997761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT02065752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study: NCT03762759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gallium Ga68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT01535573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 20 mg once per day for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 40 mg per day for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg per day for 9 weeks